Clinical significance of serum angiocidin levels in hepatocellular carcinoma
- 18 June 2007
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 251 (1), 28-35
- https://doi.org/10.1016/j.canlet.2006.10.023
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Integrin α2β1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated proteinExperimental Cell Research, 2006
- Serum tumor markers for detection of hepatocellular carcinomaWorld Journal of Gastroenterology, 2006
- Clinical Significance of Thrombospondin 1 Expression in Hepatocellular CarcinomaClinical Cancer Research, 2004
- Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin‐1Journal of Cellular Biochemistry, 2004
- Treatment of hepatocellular carcinoma: is there an optimal strategy?Cancer Treatment Reviews, 2003
- Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic featuresCancer, 2002
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disordersBritish Journal of Haematology, 1996
- Computer-assisted image analysis of tumor sections for a new thrombospondin receptorThe American Journal of Surgery, 1994
- Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.The Journal of cell biology, 1993